Work Here?
Overview
Cerebrae provides financial solutions for the healthcare industry through a subscription platform that helps healthcare providers and insurers manage financial risk and opportunities in value-based care (VBC). Its suite includes pricing, underwriting, contracting, and actuarial analytics to track savings, monitor performance over time, and build ROI models. The platform enables clients to tailor VBC strategies, map expected utilization to contracts to evaluate profit and loss, and assess the financial risk and potential of risk-sharing revenue models. Cerebrae differentiates itself by focusing on the healthcare sector and VBC-specific financial tooling, offering an integrated, contract-aware toolkit that speeds up deal diligence and financial planning. The company’s goal is to help healthcare organizations optimize financial performance and manage risk as they transition to value-based care.
About Cerebrae
Industries
Data & Analytics
Enterprise Software
Financial Services
Healthcare
Company Size
1-10
Company Stage
Series A
Total Funding
$16.5M
Headquarters
San Francisco, California
Founded
2019
Simplify's Take
What believers are saying
- VBC payments exceed 50% of U.S. healthcare by 2026 with 92% payer contract growth.
- Sonrava Health partnership integrates PreTRM® test into employer maternity benefits.
- Series A from Stepstone Group validates actuarial tools for VBC scaling.
What critics are saying
- Cerebras Systems enables insurers to build in-house AI models 10x faster.
- OpenAI o1 outperforms actuarial science in VBC risk prediction within 12 months.
- COEBRA's AI platform automates VBC contracts, eroding Accorded's edge.
What makes Cerebrae unique
- Accorded rebranded from Cerebrae in 2022 to focus on frictionless value-based contracting.
- Contract Designer enables dynamic VBC term design and payer-provider collaboration.
- Actuarial-powered Opportunity Forecast projects cost-of-care impacts pre-contract.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$16.5M
Above
Industry Average
Funded Over
0 Rounds
Company News
The value created by applying Sera's PreTRM® test and treat strategy enables savings to be shared in an innovative value-based paradigm. SALT LAKE CITY, COPPELL, Texas and SAN MATEO, Calif., Oct. 4, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, Sonrava Health, a national family of health and wellness companies, and Cerebrae, an innovator in pricing and measuring the financial value of care, are collaborating to provide Sera's PreTRM® Test to members of Sonrava Health's employer-sponsored health insurance program. The PreTRM® Test is the only broadly clinically validated, commercially available blood test that provides an early, individual risk assessment for spontaneous preterm birth in asymptomatic, singleton pregnancies. Sera's PreTRM® Test identifies nearly 90% of pregnancies where spontaneous preterm deliveries will occur, enabling earlier proactive intervention designed to improve the well-being of mothers and babies
There are no jobs for Cerebrae right now.
Find jobs on Simplify and start your career today
About Cerebrae
Industries
Data & Analytics
Enterprise Software
Financial Services
Healthcare
Company Size
1-10
Company Stage
Series A
Total Funding
$16.5M
Headquarters
San Francisco, California
Founded
2019
There are no jobs for Cerebrae right now.
Find jobs on Simplify and start your career today